Use of oxandrolone in the treatment of burns and other wounds

• US 6,828,313 B2
• Filed: 10/22/2001
• Issued: 12/07/2004
• Est. Priority Date: 12/05/1996
• Status: Expired due to Term

• Current Assignee: Gemini Laboratories, LLC
• Original Assignee: Savient Pharmaceuticals Incorporated (Amgen Inc.)
• Inventors: Fishbein, Don
• Primary Examiner(s): Krass, Frederick
• Assistant Examiner(s): Lewis, Amy
• Application Number:
  US10/011,377
• Publication Number:
  US 20020165266A1
• Time in Patent Office: 1,142 Days
• Field of Search: 514/2, 514/171, 514/175, 514/179, 514/925, 514/928
• US Class Current: 514/171
• CPC Class Codes: A61K 31/366 having six-membered rings, e.g. delta-lactones
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00

Abstract

The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.

Claims

1. A method of increasing the rate of healing of a skin wound in a patient suffering from a skin wound which comprises administering a therapeutically effective amount of oxandrolone to the patient.

2. A method according to claim 1 wherein the skin wound is an ulcer.

3. A method according to claim 2 wherein the ulcer is a decubitus ulcer or a diabetic ulcer.

4. A method according to claim 1 wherein the skin wound comprises a skin graft.

5. A method according to claim 1 wherein the skin wound is a burn.

6. A method according to claim 1 wherein the amount of oxandrolone is about 1-100 mg per day.

7. A method according to claim 6 wherein the amount of oxandrolone is about 80 mg per day.

8. A method according to claim 6 wherein the amount of oxandrolone is about 20 mg per day.

9. A method according to claim 6 wherein the amount of oxandrolone is about 10 mg per day.

10. A method according to claim 6 wherein the amount of oxandrolone is about 2.5 mg per day.

11. A method according to claim 1 wherein the oxandrolone is administered orally.

12. A method according to claim 1 wherein the oxandrolone is administered topically.

13. A method according to claim 1 wherein the oxandrolone is administered by injection.

14. A method according to claim 1 wherein the oxandrolone is in a solid dosage form.

15. A method according to claim 1 wherein the oxandrolone is in a liquid dosage form.

16. A method according to claim 1 wherein the oxandrolone is in a sustained-release formulation.

17. A method according to claim 1 wherein the oxandrolone is 17α

-methyl-17β

-hydroxy-2-oxa-5α

-androstan-3-one.

18. A method of increasing the rate of weight gain during the recovery phase after burn-induced weight loss in a patient having a burn wound which comprises administering a therapeutically effective amount of oxandrolone to the patient.

19. A method according to claim 18 wherein the amount of oxandrolone is about 1-100 mg per day.

20. A method according to claim 19 wherein the amount of oxandrolone is about 80 mg per day.

21. A method according to claim 19 wherein the amount of oxandrolone is about 20 mg per day.

22. A method according to claim 19 wherein the amount of oxandrolone is about 10 mg per day.

23. A method according to claim 19 wherein the amount of oxandrolone is about 2.5 mg per day.

24. A method according to claim 18 wherein the oxandrolone is administered orally.

25. A method according to claim 18 wherein the oxandrolone is administered topically.

26. A method according to claim 18 wherein the oxandrolone is administered by injection.

27. A method according to claim 18 wherein the oxandrolone is in a solid dosage form.

28. A method according to claim 18 wherein the oxandrolone is in a liquid dosage form.

29. A method according to claim 18 wherein the oxandrolone is in a sustained-release formulation.

30. A method according to claim 18 wherein the oxandrolone is 17α

-methyl-17β

-hydroxy-2-oxa-5α

-androstan-3-one.

31. A method according to claim 18 further comprising administering a protein supplement.

32. A method according to claim 18 wherein the weight comprises lean body mass.

33. A method according to claim 18 wherein the weight gained is maintained.